CalciMedica (CALC) vs Theriva Biologics (TOVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Theriva Biologics (TOVX) has outperformed CalciMedica (CALC) over the past year, losing 49.5% versus a loss of 91.8%. Theriva Biologics is the larger company by market cap ($10.4 million vs $8.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CALC | TOVX |
|---|---|---|
| Share price | $1.30 | $0.2271 |
| Market cap | $8.88M | $10.42M |
| 1-day change | -12.16% | -2.95% |
| YTD return | -96.05% | +8.14% |
| 1-year return | -91.84% | -49.53% |
| 5-year return | — | -99.79% |
| P/E ratio (TTM) | — | 0.30 |
| EPS (TTM) | $-6.85 | $0.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $36.00 | $0.86 |
| 52-week low | $1.30 | $0.16 |
| Distance from 52-week high | -96.39% | -73.59% |
| Analyst consensus | none | none |
| Avg. price target upside | +3746.15% | +1000.84% |
| Average volume | 75.54K | 530.02K |
| Shares outstanding | 6.83M | 45.89M |
| Employees | 15 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TOVX has outperformed CALC by 42.3 percentage points over the past year.
About CalciMedica
CALC stock →CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About Theriva Biologics
TOVX stock →Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
CALC vs TOVX FAQ
Which is bigger, CalciMedica or Theriva Biologics?
Theriva Biologics (TOVX) is larger, with a market capitalization of $10.42M compared with $8.88M for CalciMedica (CALC).
Which stock has performed better over the past year, CALC or TOVX?
TOVX returned -49.53% over the past 12 months, compared with -91.84% for CALC (price return, excluding dividends). Past performance does not predict future results.
Are CalciMedica and Theriva Biologics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.